Monopar Therapeutics Inc. (MNPR) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on two primary areas: the development of ALXN1840 for Wilson disease (a rare genetic disorder) and a pipeline of radiopharmaceuticals targeting uPAR-expressing cancers (MNPR-101 series). The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9.21) million | $(5.08) million |
| Net Loss Per Share (Basic & Diluted) | $(1.08) | $(0.73) |
| Operating Expenses | $11.87 million | $6.46 million |
| Research & Development (R&D) | $8.25 million | $3.37 million |
| General & Administrative (G&A) | $3.62 million | $3.08 million |
| Interest Income | $2.63 million | $1.38 million |
| Cash, Cash Equivalents & Investments | $134.30 million | $118.40 million (Dec 31, 2025) |
| Accumulated Deficit | $(98.72) million | $(80.87) million (June 30, 2025) |
| Net Cash Used in Operating Activities | $(6.72) million | $(6.74) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2026, increased by approximately $4.13 million compared to the same period in 2025. This was driven primarily by a $4.88 million increase in R&D expenses and a $0.53 million increase in G&A expenses.
- R&D Expense Surge: R&D expenses rose significantly due to increased contractor/consulting fees ($2.85 million increase), higher personnel costs ($1.52 million increase), and manufacturing activities related to ALXN1840 ($0.49 million increase).
- Higher Interest Income: Interest income increased by $1.25 million year-over-year, attributed to higher bank balances resulting from the September 2025 capital raise and interest earned on U.S. Treasury securities and commercial paper.
- Cash Position: Total cash, cash equivalents, and investments stood at $134.3 million as of June 30, 2026, down slightly from $140.5 million at year-end 2025, reflecting operational burn offset by investment income.
Guidance, Outlook, and Management Commentary
- Liquidity Outlook: Management estimates that current funds will support operations through at least December 31, 2027. The company has no substantial doubt about its ability to continue as a going concern.
- ALXN1840 (Wilson Disease):
- The company initiated a rolling submission of the New Drug Application (NDA) on July 22, 2026, with completion expected within the next few months.
- Recent data presentations (EASL, ANA, EAN) highlighted sustained neurological improvements, copper mobilization, and a favorable safety profile over 6+ years of treatment.
- On June 30, 2026, the FDA granted Rare Pediatric Disease (RPD) designation, potentially qualifying the company for a Priority Review Voucher upon approval.
- Context: The program was previously terminated by Alexion (AstraZeneca) in 2024 based on Phase 2 mechanistic trial reviews, though Monopar's subsequent analysis of Phase 3 data supports efficacy.
- Radiopharmaceutical Pipeline (MNPR-101):
- MNPR-101-Zr: Phase 1 imaging trial is active; FDA authorized an Expanded Access Program (EAP) in September 2025.
- MNPR-101-Lu: Phase 1a therapeutic trial is active; FDA cleared the IND in September 2025.
- MNPR-101-Ac: Late preclinical stage; advancing toward clinical trials.
- Risks and Contingencies:
- Regulatory Uncertainty: No assurance that the FDA will accept the NDA for filing or approve ALXN1840.
- Capital Requirements: Future funding is required for commercialization if approved, and for continued clinical development. The company may need to raise additional capital through equity or debt, which could dilute shareholders.
- Supply Chain: Risks related to the availability and cost of radioisotopes (e.g., Actinium-225) and geopolitical impacts on manufacturing.
Key Facts for Investor Verification
- NDA Submission Status: Verify the acceptance of the rolling NDA submission for ALXN1840 by the FDA and any subsequent requests for additional data.
- Cash Runway: Confirm the burn rate and whether the projected runway through end of 2027 holds given the increased R&D spend.
- ALXN1840 Regulatory History: Review the specific reasons for Alexion's 2024 termination of the program versus Monopar's current interpretation of the Phase 3 data.
- Capital Raise Terms: Review the details of the September 2025 offering and the concurrent share repurchase from Tactic Pharma to understand current ownership dilution.
- Radiopharmaceutical Progress: Monitor enrollment and safety data from the MNPR-101-Zr and MNPR-101-Lu Phase 1 trials.